Company Description
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson’s disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
The company’s proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata.
In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform.
The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
| Country | United States |
| Founded | 2004 |
| IPO Date | Jul 25, 2018 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 142 |
| CEO | Daniel Barber |
Contact Details
Address: 30 Technology Drive Warren, New Jersey 07059 United States | |
| Phone | 908 941 1900 |
| Website | aquestive.com |
Stock Details
| Ticker Symbol | AQST |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001398733 |
| CUSIP Number | 03843E104 |
| ISIN Number | US03843E1047 |
| Employer ID | 20-8623253 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Daniel Barber | Chief Executive Officer, President and Director |
| Alexander Mark Schobel | Chief Innovation and Technology Officer |
| Lori J. Braender BSBA, Esq., J.D. | Chief Legal Officer, Chief Compliance Officer and Secretary |
| A. Ernest Toth Jr. | Chief Financial Officer |
| Cassie Jung | Chief Operating Officer |
| Sherry Korczynski | Senior Vice President of Sales and Marketing |
| Peter E. Boyd | Senior Vice President of Information Technology and Human Resources |
| Dr. Gary H. Slatko M.D., MBA | Chief Medical Officer |
| Dr. Carl N. Kraus M.D. | Chief Medical Officer |
| Dr. Melina T. Cioffi | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2025 | 10-Q | Quarterly Report |
| May 12, 2025 | 8-K | Current Report |
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 1, 2025 | 8-K | Current Report |
| Mar 10, 2025 | 8-K | Current Report |
| Mar 5, 2025 | 10-K | Annual Report |
| Mar 5, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |